Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신진호 | - |
dc.date.accessioned | 2022-09-28T04:49:59Z | - |
dc.date.available | 2022-09-28T04:49:59Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.citation | Drug Design, Development and Therapy, v. 14, page. 1-8 | en_US |
dc.identifier.issn | 1177-8881 | en_US |
dc.identifier.uri | https://www.dovepress.com/low-dose-triple-antihypertensive-combination-therapy-in-patients-with--peer-reviewed-fulltext-article-DDDT | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/174984 | - |
dc.description.abstract | Purpose: We evaluated the dose-responsiveness, efficacy, and safety of low-dose triple antihypertensive combination therapies in patients with mild-to-moderate hypertension. Patients and Methods: After a 1 to 2-week placebo run-in period, 248 patients were randomized to the half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg), third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg), quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13mg), amlodipine 10mg, amlodipine 5mg, losartan 100mg, and placebo groups for 8 weeks. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to week 8. Results: The placebo-corrected SBP reductions of the half-dose, third-dose, quarter-dose combination, amlodipine 10 mg, amlodipine 5 mg and losartan 100 mg treatments were − 17.2, − 19.5, − 14.9, − 18.5, − 11.3 and − 9.9 mmHg, respectively. The BP control and response rates were significantly higher in the half-dose, third-dose, and quarter-dose combination groups than in the placebo group (all p < 0.01). Despite no intergroup differences in study drug-related adverse events, ankle circumference increased significantly in the amlodipine group compared to those in the combination treatment groups. The quarter-dose combination, amlodipine 5 mg, and losartan 100 mg groups showed similar SBP reduction and BP response rates. The SBP reduction and BP response rate in the third-dose and half-dose combination groups were not significantly different from those in the amlodipine 10 mg group but superior to those in the losartan 100 mg group. Conclusion: Low-dose triple combination therapies could be effective as antihypertensive therapies. | en_US |
dc.description.sponsorship | Funding was provided by Hanmi Pharmaceutical Co. Ltd., Seoul, Republic of Korea. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Dove Medical Press Ltd | en_US |
dc.subject | hypertension; blood pressure; combination therapy; low-dose; amlodipine; losartan; chlorthalidone | en_US |
dc.title | Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.2147/DDDT.S286586 | en_US |
dc.relation.page | 1-8 | - |
dc.relation.journal | Drug Design, Development and Therapy | - |
dc.contributor.googleauthor | Hong, Soon Jun | - |
dc.contributor.googleauthor | Sung, Ki-Chul | - |
dc.contributor.googleauthor | Lim, Sang-Wook | - |
dc.contributor.googleauthor | Kim, Seok-Yeon | - |
dc.contributor.googleauthor | Kim, Weon | - |
dc.contributor.googleauthor | Shin, Jinho | - |
dc.contributor.googleauthor | Park, Sungha | - |
dc.contributor.googleauthor | Kim, Hae-Young | - |
dc.contributor.googleauthor | Rhee, Moo-Yong | - |
dc.relation.code | 2020006175 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | jhs2003 | - |
dc.identifier.orcid | https://orcid.org/0000-0001-6706-6504 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.